DN1 ECONOMIC EVALUATIONOF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY  by Busca, R et al.
A14 Abstracts
the ﬁrst 12-month observational period. Out of 505 total sub-
jects enrolled at (12 months) follow-up, 467 patients fully com-
pleted ICIQ-LF. The average variation observed in patients’
reported overall “impact of symptoms” was -1.92 (SD 3.36;
range -7; 10), suggesting a reported improvement in QoL from
baseline. The frequency of women who complained of urine
leakage shows a signiﬁcant decrease from baseline to follow up
(68% Vs 55.6%). Consistently, the number of patients com-
plaining of limited activities due to urinary leakage decreased
from 56.5% to 42%. The W-IPSS was compiled by 83% of all
subjects. For all symptoms considered, greater improvement in
QoL was observed were symptoms showed higher remission
rates and lower persistency and incidence rates. An overall
improvement was conﬁrmed also by SF-36. RESULTS: 49.2%
of patients at follow-up reported a good health status (to various
degrees) versus 10.7% at baseline. CONCLUSION: According
to ICIQ-LF and W-IPSS an overall condition improvement was
registered at 12 months from baseline with respect to all LUT
symptoms (storage, voiding and post-micturition categories). A
correlation between increased QoL and observed symptoms
remission rates was detected by all questionnaires.
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OBJECTIVE: Hemophilia treatment has prolonged patients’ life
expectancy and is now focused on improving their Health-
Related Quality-of-Life (HRQoL). We evaluated HRQoL of
adult hemophilic patients without inhibitors. METHODS: The
Cost Of Care of HEmophilia (COCHE) study is a naturalistic,
multicenter, longitudinal study. Patients without inhibitors aged
>18 years were sequentially enrolled at 23 Italian Hemophilia
Care Centers. Information collected was on: socio-demograph-
ics, clinical, resource absorption (direct, indirect costs), HRQoL
(intangible costs) and treatment satisfaction. The following
results pertain to the HRQoL evaluated with two generic instru-
ments: EuroQol (EQ-5D) and Short Form-36 (SF-36). RESULTS:
232 patients were enrolled (median age = 34.3, ranging from 18
to 74), 86.6% with hemophilia A, 72.4% severely affected. At
the time of enrolment 81.0% of patients had chronic hepatic C,
25.0% hepatitis B, 15.9% HIV infection. Most of the patients
(87.8%) reported some orthopedic problems. Target joints were
present in 57.0% of patients. Bleeding occurred on average 2.10
times per patient/month (median 1.44, ranging from 0 to 26).
EQ-5D proﬁle showed that 77.9% of patients complained of
moderate or extreme “pain/discomfort”, 63.5% had problems
with “mobility”, 48.9% were anxious or depressed, 40% had
problems in doing “usual activities”, 12.2% problems with “self-
care”. EQ-Visual Analogue Scale had a mean value of 66.2
(median 70.0, ranging from 9 to 100). The mean+/-SD utility
score was 0.7+/-0.2 (median 0.7, ranging from -0.2 to 1). These
results were conﬁrmed by the SF-36: in particular, the mean+/-
SD Physical Component Summary score was 36.9+/-10.7
(median 35.2, from 15.2 to 55.0); the mean+/-SD Mental Com-
ponent Summary score was 50.2+/-11.8, (median 52.8, from
15.5 to 68.1). CONCLUSION: Hemophilic patients without
inhibitors showed impaired levels of general HRQoL. In partic-
ular the physical component of HRQoL was sensitively com-
promised; by contrast the mental component was relatively good
in comparison to the general Italian male population.
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OBJECTIVES: This study assessed the economic value of using
SPECT-DaTSCAN (123I-FP-CIT) in comparison with current
clinical judgment, in the diagnosis of patients with clinically
uncertain Parkinsonism in Italy. METHODS: A cost-effective-
ness analysis was based on a Markov model, comparing a cohort
of patients following a diagnostic pathway including or exclud-
ing DaTSCAN, using a time horizon of 5 years. The model was
populated with direct medical costs (drugs, tests, exams, hospi-
tal admissions, management of adverse events) associated with
diagnosis and treatment, diagnostic accuracy (sensitivity: 97%,
speciﬁcity: 100%), the underlying prevalence of diseases in the
tested population (estimated to be 49%), rates of adverse events,
therapy progression and death. Effectiveness was expressed as
the (gain in) number of years of appropriate therapy per patient.
Model input values were estimated using a double round Delphi
panel performed with 12 Italian specialists. Diagnostic accuracy,
adverse event rates and mortality rates were based on published
studies. RESULTS: The current diagnostic pathway produced on
average 2.3 “adequately treated years” (ATYs) per patient at an
estimated cost of €8893 to the health care system over 5 years.
The DaTSCAN pathway generated on average 4.1 ATYs per
patient at an estimated cost of €8410. Use of DaTSCAN rather
than current diagnostic practice generated an additional 1.8
ATYs at a cost saving of €482 per patient over 5 years. Dis-
counting at 5%, the cost saving became €372 per patient over 5
years. If the use of DaTSCAN decreased other diagnostic work-
up costs by €450 (estimated by clinical expert), cost savings
became €932 (undiscounted) per patient tested. The result is sen-
sitive to the proportion of patients tested. CONCLUSION: The
analysis suggests that using DaTSCAN in patients with clinically
uncertain Parkinsonism is an economically attractive interven-
tion. Greater amounts of time on appropriate therapy are
achieved at less cost to the health care system.
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OBJECTIVES: Self monitoring of blood glucose (SMBG) has
been shown to improve glycemic control of type 2 diabetes in
previous studies (HbA1c improved by 0.3–0.6% with SMBG
versus no SMBG, depending on treatment received) However, the
cost of testing supplies is high and cost-effectiveness has not been
evaluated. METHODS: A validated model (CORE Diabetes
model) projected improvements in lifetime quality-adjusted life
years (QALY), long-term costs, and cost-effectiveness of SMBG
versus no SMBG. Markov/Monte Carlo modeling simulated pro-
gression of complications (cardiovascular, neuropathy, renal and
